Aurora Cannabis Inc. (ACB.TO) is seeing a notable drop in its stock price, which fell 1.43% in the last trading session.
On a tough trading day, Aurora's stock price dropped to CA$4.13, raising ongoing concerns about its profitability and market strategy. While the company reported strong revenue from medical cannabis, its stock is struggling to gain traction.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Aurora Cannabis Inc
ACB.TO
ACB.TO
Aurora Cannabis Inc
WealthAwesomeMarket cap
$240.34M
52W high
$9.33
52W low
$3.59
1W change
+2.92%
Beta
1.35
Analyst Price Targets
Based on analyst covering ACB
Wall Street analysts forecast ACB stock price to rise 45.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$5.64
+45.4% Upside
Current Price
C$3.88
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ACB's historical volatility
30-Day Vol
34.7%
Annualized
90-Day Vol
48.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.25
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.66 | C$3.24 – C$4.12 |
| 60 trading days | C$3.44 | C$2.91 – C$4.08 |
| 90 trading days | C$3.25 | C$2.64 – C$3.99 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Aurora's strategic changes and market conditions, especially with the recent decline in consumer cannabis sales and the effects of pricing adjustments in the Canadian market.
Aurora Cannabis Inc. stock down 1.43% today
Despite a solid revenue report, the stock's decline highlights worries about profitability and market strategy.
Bull case
Aurora's medical cannabis sector showed strong growth, with an 18% increase in revenue. This suggests there’s potential for long-term recovery and profitability as the company focuses on higher-margin global markets.
Bear case
The sharp decline in consumer cannabis sales and the expected pricing adjustments in the Canadian market could negatively impact Aurora's financial performance in the short term, leading to increased skepticism among investors.
Recent Performance Overview
Advertisement
Aurora Cannabis Inc. experienced a 1.43% drop in its stock price during the last trading session, closing at CA$4.13. This decline comes despite an 11% increase in net revenue for FY26, primarily driven by medical cannabis sales. Investors are now weighing the company's strategic transition against its current market challenges.
Market Challenges Ahead
The cannabis sector is facing significant challenges, especially in Canada, where pricing adjustments are expected to affect profitability. Aurora's decision to wind down lower-margin consumer cannabis operations might lead to short-term revenue dips, as shown by a 55% year-over-year decline in consumer cannabis sales. This strategic shift aims to focus on higher-margin medical markets, but it raises questions about the company's immediate financial outlook.
Looking Forward
As Aurora navigates these challenges, investors should stay alert. The company’s strong performance in medical cannabis may lay the groundwork for recovery, but the upcoming fiscal year will be crucial in determining whether Aurora can adapt to the changing market landscape. The recent decline in stock price serves as a reminder of the volatility in the cannabis industry.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
